Network Meta-Analysis On Prevention Of Stroke For Patent Foramen Ovale Closure.

1. Alushi, B., Biasco, L., Orzan, F., Omede, P., Sciuto, F., Moretti, C., . . . Gaita, F. (2014). Patent foramen ovale treatment strategy: an Italian large prospective study. J Cardiovasc Med (Hagerstown), 15(10), 761-768. doi: 10.2459/jcm.0000000000000138 2. Baglini, R., Baldari, D., Amaducci, A., & D'Ancona, G. (2013). The new patent foramen ovale occluder FIGULLA in complex septal anatomy: a case series. Ther Adv Cardiovasc Dis, 7(1), 21-26. doi: 10.1177/1753944712468628 3. Bissessor, N., Wong, A. W., Hourigan, L. A., Jayasinghe, R. S., Scalia, G. S., Burstow, D. J., . . . Walters, D. L. (2011). Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices. Cardiovasc Revasc Med, 12(3), 164-169. doi: 10.1016/j.carrev.2010.06.001 4. Brenner, R., Pratali, L., Rimoldi, S. F., Murillo Jauregui, C. X., Soria, R., Rexhaj, E., . . . Scherrer, U. (2015). Exaggerated pulmonary hypertension and right ventricular dysfunction in high-altitude dwellers with patent foramen ovale. Chest, 147(4), 1072-1079. doi: 10.1378/chest.14-1353 5. Caobelli, F., Paghera, B., Panarotto, M. B., Terzi, A., Rodella, C., Biasiotto, G., & Giubbini, R. (2011). 99mTc-MAA lung scan can be an alternative in detection and follow-up of patent foramen ovale. Int J Cardiol, 147(2), 296-298. doi: 10.1016/j.ijcard.2010.12.045 6. Carroll, J. D., Saver, J. L., Thaler, D. E., Smalling, R. W., Berry, S., MacDonald, L. A., . . . Tirschwell, D. L. (2013). Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med, 368(12), 1092-1100. doi: 10.1056/NEJMoa1301440 7. Chambers, J., Seed, P. T., & Ridsdale, L. (2013). Association of migraine aura with patent foramen ovale and atrial septal aneurysms. Int J Cardiol, 168(4), 3949-3953. doi: 10.1016/j.ijcard.2013.06.054 8. Collins, N. J., Hatton, R., Ng, K., Bhagwandeen, R., Attia, J., Oldmeadow, C., & Jayasinghe, R. (2012). Percutaneous device closure of patent foramen ovale using the Premere occlusion device: initial experience, procedural, and intermediate-term results. J Invasive Cardiol, 24(4), 164-168. References § We identified 1430 references and found 10 studies on four randomized trials in 2963 patients. § The devices included in our study were Amplatzer (AMP), STARFlex (STF), and HELEX (HLX). § The odds ratios (ORs) for AMP versus HLX were 0.54 (0.05 -5.38), AMP versus Medical 0.37 (0.07-1.35), AMP versus SLX 0.36 (0.05-1.87), HLX versus Medical 0.68 (0.05-7.78), HLX versus SLX 0.66 (0.07-6.00) and Medical versus SLX 0.99 (0.18-5.53). § The probability to be best in preventing strokes was 66.7% for AMP, 25.8% for HLX, 4.5% for STF, and 2.9% for medical therapy. Introduction